Abstract
Universal HBV screening before immunosuppression is prudent and cost effective, even when local HBV prevalence is just 0.3%.
MeSH terms
-
Hepatitis B / immunology*
-
Hepatitis B / prevention & control*
-
Hepatitis B Surface Antigens / immunology
-
Humans
-
Immunoglobulin G / immunology
-
Immunoglobulin M / immunology
-
Immunosuppression Therapy / adverse effects*
-
Recurrence
Substances
-
Hepatitis B Surface Antigens
-
Immunoglobulin G
-
Immunoglobulin M